NanoKnife System (AngioDynamics Inc.) for irreversible electroporation treatment of pancreatic cancer
Record ID 32014000977
English
Authors' objectives:
An estimated 46,420 individuals in the United States will be diagnosed with pancreatic cancer in 2014 and nearly 40,000 will die from the disease. Surgery can cure early disease but most patients present with unresectable disease. Standard therapies for patients with locally advanced disease are chemotherapy and radiotherapy (RT), but response rates are low. Locally advanced pancreatic cancer, defined as disease encasing the celiac or superior mesenteric artery, is considered unresectable. However, in some cases, tumors can be downstaged by chemotherapy or RT allowing for resection. Techniques such as radiofrequency ablation and microwave ablation are increasingly used in conjunction with or following standard therapies. In addition to treating the cancer, palliation of intractable pain in patients with pancreatic cancer is another important goal. Thermal ablation methods heat the tissue, causing denaturation of proteins. The resultant zone of tissue destruction surrounding the intended target can cause damage to normal pancreatic tissue
and to nearby organs such as the duodenum, stomach, superior mesenteric vessels, and portal vein, which leads to the need for alternative therapies.
Details
Project Status:
Completed
Year Published:
2014
URL for published report:
The report may be purchased from: http://www.hayesinc.com/hayes/crd/?crd=16731
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
United States
MeSH Terms
- Catheter Ablation
- Electroporation
Contact
Organisation Name:
HAYES, Inc.
Contact Address:
157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218
Contact Name:
saleinfo@hayesinc.com
Contact Email:
saleinfo@hayesinc.com
Copyright:
2014 Winifred S. Hayes, Inc
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.